Ibandronate versus zoledronic acid after stopping denosumab in postmenopausal osteoporosis
Compares two infused bone drugs after denosumab in women with osteoporosis.
Plain-language title generated from the registry record
Registry title: The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation
Key facts
- Where
- Taipei, TaiwanSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 85 years old?
Source: NCT07406685, who can take part
Where in Taiwan
- National Taiwan University HospitalTaipei, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Taiwan University Hospital
- Trial code
- NCT07406685
- Record updated
- 25 August 2026
- Original description
This study is a prospective, multicenter, open-label, randomized non-inferiority trial comparing intravenous ibandronate and zoledronic acid as sequential therapy after denosumab discontinuation in postmenopausal women with osteoporosis. This trial primarily targets patients with short-term denosumab exposure (less than three years) and is conducted as a preliminary investigation. The findings are expected to provide foundational evidence to inform the design of future studies assessing sequential therapies following longer-term denosumab treatment.Read full original descriptionShow less
The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation: A Randomized Non-inferiority Trial
This study is a prospective, multicenter, open-label, randomized non-inferiority trial comparing intravenous ibandronate and zoledronic acid as sequential therapy after denosumab discontinuation in postmenopausal women with osteoporosis. This trial primarily targets patients with short-term denosumab exposure (less than three years) and is conducted as a preliminary investigation. The findings are expected to provide foundational evidence to inform the design of future studies assessing sequential therapies following longer-term denosumab treatment.
Inclusion: Postmenopausal women aged 50 to 85 years; BMD T-score ≤ -1.5 and > -3.0 at the lumbar spine or total hip; Regular treatment with denosumab administered every 6 months for at least 1 year and less than 3 years (3 to 5 doses); Physically and mentally capable of understanding and complying with the study protocol and follow-up; Signed informed consent.
Exclusion: Current or prior treatment within the past 12 months with osteoporosis medications other than denosumab, including Romosozumab, Teriparatide, Alendronate, Ibandronate, Zoledronic acid, Risedronate and Raloxifene; Requirement for long-term use of medications known to affect bone metabolism (e.g., systemic glucocorticoids or hormone therapy); Planned dental procedures (e.g., extractions, implants) within the next year; History of fragility or osteoporotic fracture within the past 12 months; Allergy to bisphosphonates; Metabolic bone diseases; Any autoimmune disease; Cancer patients, except for in situ carcinoma and non-melanoma skin cancer, unless fully treated and in remission for five years; Vitamin D deficiency (serum 25-hydroxyvitamin D < 25 ng/mL); Renal disease (eGFR < 35 mL/min/1.73 m²) or dialysis patients; Secondary osteoporosis; Primary or metastatic bone tumors; Hypocalcemia; Smoking more than one pack per day (except for those who have quit for over ten years).